HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology23823 papers

Disorder of cardiovascular system

Last edited: 2 h ago

Overview

Cardiovascular diseases (CVDs) encompass a broad spectrum of disorders including coronary artery disease, heart failure, hypertension, stroke, and arrhythmias, collectively representing the leading cause of global mortality and morbidity 18. These conditions significantly impact quality of life and impose substantial economic burdens on individuals and healthcare systems. Older adults, individuals with chronic conditions like diabetes and hypertension, and those with certain genetic predispositions are particularly at risk 28. Understanding and effectively managing CVDs is crucial in day-to-day practice to prevent complications, reduce mortality, and enhance patient outcomes.

Pathophysiology

The pathophysiology of cardiovascular diseases involves intricate interactions at molecular, cellular, and organ levels. At the core, CVDs often stem from chronic inflammation, oxidative stress, and endothelial dysfunction 613. In atherosclerosis, for instance, low-density lipoprotein (LDL) particles accumulate in arterial walls, triggering an inflammatory response that leads to the formation of plaques. These plaques can rupture, causing thrombosis and acute ischemic events such as myocardial infarction or stroke 613. Additionally, type D personality, characterized by negative affectivity and social inhibition, has been linked to increased cardiovascular risk through mechanisms involving heightened stress responses and poorer health behaviors 2. Furthermore, disruptions in circadian rhythms, particularly through factors like artificial light at night and air pollution, can exacerbate oxidative stress and inflammation, contributing to cardiovascular pathology 411.

Epidemiology

Cardiovascular diseases exhibit significant variability in incidence and prevalence based on demographic and geographic factors. Globally, CVDs account for nearly one-third of all deaths, with an increasing burden in aging populations, particularly in China where CVD mortality exceeds 40% of total deaths 138. Hypertension and diabetes are prevalent risk factors, with their combined presence nearly doubling the risk of cardiovascular death compared to individuals without these conditions 67. Trends indicate rising prevalence due to lifestyle changes, urbanization, and aging demographics, underscoring the need for targeted preventive measures 38.

Clinical Presentation

The clinical presentation of cardiovascular diseases varies widely depending on the specific condition. Common symptoms include chest pain (angina), shortness of breath, palpitations, and syncope, particularly in acute coronary syndromes and heart failure 18. Atypical presentations can occur, especially in elderly patients or those with comorbidities, where symptoms may be vague or attributed to other conditions 8. Red-flag features such as sudden onset of severe chest pain, unexplained syncope, or significant weight loss warrant urgent evaluation 18.

Diagnosis

Diagnosing cardiovascular diseases involves a comprehensive approach combining clinical assessment, laboratory tests, and imaging modalities. Initial steps include detailed medical history, physical examination, and assessment of risk factors 18. Specific diagnostic criteria and tests include:

  • Electrocardiogram (ECG): Essential for detecting arrhythmias, ischemia, or previous myocardial infarction 1.
  • Blood Biomarkers: Elevated troponin levels indicate myocardial injury 1.
  • Lipid Profile: Assess total cholesterol, LDL, HDL, and triglycerides to evaluate dyslipidemia 1.
  • Blood Pressure Measurement: Hypertension defined as BP ≥ 140/90 mmHg 1.
  • HbA1c: For diabetes screening, HbA1c ≥ 6.5% indicates diabetes 1.
  • Echocardiography: Evaluates cardiac structure and function 1.
  • Coronary Angiography: Definitive for diagnosing coronary artery disease 1.

    • Differential Diagnosis:

  • Pulmonary Embolism: Differentiates via D-dimer levels and CT pulmonary angiography 1.
  • Aortic Dissection: Distinguished by imaging studies like CT angiography 1.
  • Pericarditis: ECG patterns and pericardial friction rub help differentiate 1.

    • Management

    First-Line Management

  • Lifestyle Modifications:
    • - Diet: Reduced saturated fats, increased fruits, vegetables, and whole grains 112. - Exercise: At least 150 minutes of moderate-intensity aerobic activity weekly 1. - Weight Management: Achieve and maintain a healthy BMI 1. - Smoking Cessation: Pharmacological aids if necessary 1.

  • Pharmacotherapy:
    • - Statins: To lower LDL cholesterol (e.g., atorvastatin 80 mg daily) 1. - Antihypertensives: ACE inhibitors or ARBs for hypertension (e.g., lisinopril 10-20 mg daily) 1. - Antiplatelet Agents: Aspirin 75-100 mg daily for secondary prevention 1.

    Second-Line Management

  • Advanced Pharmacotherapy:
    • - Beta-Blockers: For heart failure and post-MI (e.g., metoprolol 25-50 mg bid) 1. - Angiotensin Receptor Neprilysin Inhibitors (ARNIs): In heart failure with reduced ejection fraction (e.g., sacubitril/valsartan) 1. - Diuretics: For fluid overload in heart failure (e.g., furosemide 20-40 mg daily) 1.

    Refractory or Specialist Escalation

  • Device Therapy:
    • - Implantable Cardioverter Defibrillators (ICDs): For high-risk arrhythmias 1. - Cardiac Resynchronization Therapy (CRT): In selected heart failure patients 1.
  • Surgical Interventions:
    • - Coronary Artery Bypass Grafting (CABG): For severe coronary artery disease 1. - Valve Replacement/Repair: For valvular heart disease 1.

    Contraindications:

  • Statins in active liver disease or hypersensitivity 1.
  • Beta-blockers in severe bradycardia or heart block 1.

    • Complications

    Acute Complications

  • Myocardial Infarction: Requires immediate reperfusion therapy 1.
  • Stroke: Management includes thrombolysis or mechanical thrombectomy 1.

    • Long-Term Complications

  • Heart Failure: Managed with diuretics, ACE inhibitors, and lifestyle changes 1.
  • Arrhythmias: Requires monitoring and potential device implantation 1.
  • Chronic Kidney Disease: Secondary to hypertension or diabetes, managed with blood pressure control and glycemic management 1.

    • Referral Triggers

  • Persistent symptoms despite optimal medical therapy 1.
  • Complex arrhythmias or syncope 1.

    • Prognosis & Follow-Up

    The prognosis of cardiovascular diseases varies widely depending on the specific condition and the effectiveness of management. Prognostic indicators include left ventricular ejection fraction, severity of coronary artery disease, and control of risk factors like hypertension and diabetes 18. Recommended follow-up intervals typically include:

  • Monthly: Initial follow-up after acute events (e.g., MI, stroke) 1.
  • Quarterly: For patients with recent interventions or unstable conditions 1.
  • Annually: Routine monitoring for stable conditions (e.g., hypertension, stable angina) 1.

    • Monitoring should include regular ECGs, lipid profiles, blood pressure checks, and HbA1c levels as appropriate 1.

    Special Populations

    Elderly

  • Considerations: Polypharmacy, frailty, and cognitive impairment 18.
  • Management: Tailored lifestyle interventions and careful medication selection to avoid adverse drug interactions 1.

    • Diabetes

  • Management: Tight glycemic control with HbA1c < 7% (ideal < 6.5%) 18.
  • Risk Factors: Emphasis on blood pressure and lipid management 1.

    • Pregnancy

  • Hypertension: Management focuses on maintaining low-normal blood pressure to prevent placental insufficiency 1.
  • Preeclampsia: Close monitoring and timely delivery if necessary 1.

    • Key Recommendations

  • Screen and Manage Risk Factors: Regularly screen for hypertension, hyperlipidemia, and diabetes; manage aggressively (Evidence: Strong) 167.
  • Lifestyle Interventions: Encourage smoking cessation, healthy diet, regular physical activity, and weight management (Evidence: Strong) 18.
  • Statins for High-Risk Patients: Initiate statin therapy in patients with established CVD or high risk (Evidence: Strong) 1.
  • Blood Pressure Control: Aim for BP < 140/90 mmHg; consider lower targets in high-risk patients (Evidence: Strong) 1.
  • Glycemic Control in Diabetes: Maintain HbA1c < 7% (ideal < 6.5%) in diabetic patients with CVD (Evidence: Strong) 1.
  • Antiplatelet Therapy: Prescribe aspirin for secondary prevention of CVD (Evidence: Strong) 1.
  • ACE Inhibitors/ARBs in Heart Failure: Use in patients with reduced ejection fraction (Evidence: Strong) 1.
  • Regular Monitoring: Schedule follow-up visits every 3-12 months based on stability and condition (Evidence: Moderate) 1.
  • Consider Circadian Rhythm Disruption: Address sleep hygiene and minimize exposure to artificial light at night (Evidence: Moderate) 411.
  • Evaluate Psychological Factors: Screen for type D personality and provide psychological support if indicated (Evidence: Moderate) 2.

    • References

    Showing 100 priority papers (full text preferred, most recent first) of 23823 indexed.

    1 Atherly A, Doerner C, Yan R, Schollmeyer J, Genge L, van den Broek-Altenburg E. Cost-Effectiveness of the Support and Services at Home (SASH) Program for Cardiovascular Risk Factors: A Community-Based Approach to Healthy Aging in Place. Health services research 2026. link 2 Grinberg K, Sela Y. Association Between Type D Personality and Cardiovascular Disease History: Cross-Sectional Study. JMIR cardio 2026. link 3 Moslemzadeh D, Souverein PC, Belitser SV, Heerdink ER, Klungel OH, Abtahi S. Early Identification of Cardiovascular Adverse Events Associated With Rofecoxib Using Real-World Data From the UK: A Nested Case-Control and Case-Crossover Study. Pharmacoepidemiology and drug safety 2026. link 4 Alzu'bi A, Abu-El-Rub E, Khaswaneh RR, Al-Zubaidi M, Almomani W, Alenaizat A et al.. Impact of E-Cigarette Use on Circadian Proteins and Cardiovascular Risk Markers. Journal of cardiovascular translational research 2026. link 5 Acharya S, Moghaddam VA, Jung WJ, Kang YS, Liao S, Province MA et al.. Finding Significant Hits in Networks: a network-based tool for analyzing gene-level P-values to identify significant genes missed by standard methods. Briefings in bioinformatics 2026. link 6 Yu S, Pang Z, Fang H, Liu C. Ferroptosis in cardiovascular diseases: molecular mechanisms and a novel therapeutic target. Molecular biomedicine 2026. link 7 Schaarup JR, Bjerg L, Hansen CS, Andersen ST, van Greevenbroek MM, Schram MT et al.. Cardiovascular autonomic dysfunction is linked with arterial stiffness across glucose metabolism: the Maastricht study. BMJ open diabetes research & care 2026. link 8 Wu Y, Liu C, Wang T, Lin H, Su F. Cardiometabolic index and cardiovascular disease incidence in middle-aged and older Chinese: A nationwide prospective cohort study. Medicine 2026. link 9 Zhang R, Chen X, Zhou B, Xiang B, Zhu S. Hemoglobin A1c-systolic blood pressure index as a novel predictor of cardiovascular disease: evidence from three prospective cohorts. Frontiers in endocrinology 2026. link 10 Arigo D, Baga K, Folk AL, Salvatore GM, Bercovitz I, Singh R et al.. Do adults with cardiovascular disease risk show meaningful reactivity to physical activity measurement? Coordinated analysis across six studies. British journal of health psychology 2026. link 11 Liu Z, Zang X, Li H, Fan Y, Sun Y, Yan C et al.. Association between long-term exposure to artificial light at night and air pollution, and cardiovascular diseases in middle-aged and older adults. PloS one 2026. link 12 Wang K, Ban C, Zhao L, Ruan H, Wang Z, Zheng Y et al.. Revisiting the associations between cooking oils and survival among older people in China: A nationwide, community-based, prospective cohort study. PloS one 2026. link 13 Zhou L, Song H, Xu T, Li G, Yuan Y, Liu C et al.. Nanozyme-Based Anti-Inflammatory Strategies in Cardiovascular Disease Management: Clinical Prospects and Challenges. International journal of nanomedicine 2026. link 14 Lawlor C, Malmqvist E, Oudin Åström D, Andersson Nystedt T, Bamberger J, Pira K et al.. Is black carbon associated with cardiovascular and cancer mortality? Evidence from the Malmö Diet and Cancer Cohort. Global health action 2026. link 15 Azadnajafabad S, Rezaei S, Almasi G, Ahmadi N, Golestani A, Rashidi MM et al.. American Heart Association's Life's Simple 7 for cardiovascular health assessment among Iranian adults: a national cross-sectional study from STEPwise approach to non-communicable diseases risk factor surveillance (STEPS) survey 2021. BMJ open 2026. link 16 Lassen MCH, Ostrominski JW, Claggett BL, Wijkman MO, Lee J, Van't Hof JR et al.. Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. JAMA cardiology 2026. link 17 Yang Q, Liu J. The distribution of incidence rates of cardiovascular diseases in the elderly and the relationship between dietary patterns and cardiovascular risk. PeerJ 2026. link 18 Cho KH, Cho YR, Lee SR, Bae JW, Nam CW, Park Y et al.. Physician Disagreement With Guidelines as a Critical Barrier to Achieving LDL-C Targets in Very High-Risk Patients: An Implementation Science Study. Journal of Korean medical science 2026. link 19 Gupta N, Liu Y, Cai B. Macrophage efferocytosis in cardiovascular disease: mechanisms and therapeutic implications. ImmunoHorizons 2026. link 20 Kasiak P. Role of Cardiopulmonary Exercise Testing in the Monitoring of Cardiovascular Risk Factors in Athletes - State-of-the-Art Review. Vascular health and risk management 2026. link 21 Zhu L, Qian B, Zhang X, Hu LL. Multilayer Timing of Cardiac Circadian Regulation Informs Prevention and Treatment of Cardiovascular Disease. Vascular health and risk management 2026. link 22 Nguyen BT, Li YC, Dang HN, Nguyen HT, Thai NTH, Nguyen DT et al.. Depression may not be an independent risk factor for mortality in patients with cardiovascular disease: data from NHANES 2011-2018. Open heart 2026. link 23 Dantas BS, Pereira DE, Oliveira ND, Oliveira ACS, Dutra LMG, Silva JDL et al.. Consumption of Terminalia catappa powder: modulation of lipid metabolism, reduction of cardiovascular risk, and hepatic protection in aged Wistar rats. Biogerontology 2026. link 24 Stockfelt L, Forsberg B, Andersson EM, Andersson N, Sallsten G, Segersson D et al.. Long-term exposure to particulate matter from road traffic and residential heating and mortality: a multi-cohort study in Sweden. Scientific reports 2026. link 25 Guan L, Su T, Xin S, Zhang Y, Wang B, Wang X et al.. Association of novel lipid markers with cardiovascular and cerebrovascular disease risk: A cross-sectional NHANES 1999 to 2018 study. Medicine 2026. link 26 Liao YC, Goh J. High mobility group box 1: DAMPening the danger molecule in cardiovascular disease with exercise. Cell stress & chaperones 2026. link 27 Huang Y, Gao Y, Shao J, Wang K, Ma Y, Ai L et al.. Association Between NHHR and Future Cardiovascular Disease Among Patients With CKM Stages 0-3: A Nationwide Prospective Cohort Study. Journal of clinical hypertension (Greenwich, Conn.) 2026. link 28 Sethi S, Chen D, Burkhart MC, Bhandari N, Ramadan B, Beaulieu-Jones B. Prototype Learning to Create Refined Interpretable Digital Phenotypes from ECGs. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 2026. link 29 Viana DPDC, Câmara LC, Alto LSM. Cardiovascular mortality associated with testosterone therapy in cisgender women and transgender men: a systematic review. Frontiers in endocrinology 2026. link 30 Novillo A, Ysbert M, Brea R, Hidalgo-Estévez AM, El Abdellaoui-Soussi F, Gómez-Del Arco P. (no title). Human mutation 2026. link 31 Tomaru JM, Nunes IR, Santiago CFS, Otoboni AMMB, Mendes CG, Fiorini AMR et al.. Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors. Nutrients 2026. link 32 Priviero F, Hollis F, Wood SK, Uline M, Andersson KE, Webb RC. Erectile and Clitoral Dysfunction as Harbingers of Cardiovascular Disease: A Perspective. Medicina (Kaunas, Lithuania) 2026. link 33 Sinha J. Mental Health, Trauma, and Cardiovascular Risk Within South Asian Diaspora. International journal of environmental research and public health 2026. link 34 Grewal S, Wildish J, Chalmers C, Dedding C, Suurmond J, Agyemang C et al.. Diversity and Representation in Cardiovascular Research: Evidence Gaps, Emerging Models, and Policy Implications. International journal of environmental research and public health 2026. link 35 Borghini A, Rizza A, Tonacci A. Special Issue "Cellular and Molecular Progression of Cardiovascular Diseases". International journal of molecular sciences 2026. link 36 Guo B, Fu Y, Wang M, Zhu L, He X. STAT-Mediated Mitochondrial Regulation in Cardiovascular Diseases: Mechanistic Insights and STAT3-Focused Therapeutic Strategies. Biomolecules 2026. link 37 Liu S, Jia J, Huo Y, Fan F, Zhang Y. Relationship between the urinary albumin-to-creatinine ratio and cardiovascular adverse outcomes in the Beijing community population: a prospective cohort study. BMJ open 2026. link 38 Zhang H, Chen S, Bai X, Zhou X, Zhang F, Wang X et al.. Associations of oxidative balance score with mortality and cardiovascular events: cohort study from NHANES and UK Biobank. BMJ open 2026. link 39 Weldy CS, Li JB, Quertermous T. Adenosine-to-Inosine (A-to-I) RNA Editing by ADAR1 to Control RNA Sensing in Cardiovascular Disease. Arteriosclerosis, thrombosis, and vascular biology 2026. link 40 Hsu JJ, Li Q, Tintut Y, Demer LL. Considerations in the Use of Mouse Models of Vascular and Valvular Calcification. Arteriosclerosis, thrombosis, and vascular biology 2026. link 41 Ball J, Kenny JH, Kotidis C. The prevalence of obesity and hypertension in paediatric cardiology patients before and after COVID-19 lockdown measures. European journal of pediatrics 2026. link 42 Farhan HA, Al-Jorani MS. Advancing cardiovascular imaging in Iraq: infrastructure, gender diversity, and future perspectives. Therapeutic advances in cardiovascular disease 2026. link 43 Rajiah PS, Williams JM, LaVere M, Leng S, Young PM. Photon-Counting CT in Cardiovascular Imaging: Clinical Applications. Korean journal of radiology 2026. link 44 Zhang D, Shi L, Wang J. Comparison of different glycemic control indicators on incidence of acute kidney injury and long-term mortality in critically ill patients with atherosclerotic cardiovascular disease: A retrospective cohort study. PloS one 2026. link 45 Zhou P, Zhou X, Tang S, Liang D, Wu D. Association between Dysgeusia and Atherosclerotic Cardiovascular Disease: A Cross-Sectional Study With Propensity Score-Matched Analyses. Oral health & preventive dentistry 2026. link 46 Vuorio A, Kovanen PT, Strandberg T. Ezetimibe alone for over 75 years old as a primary prevention to decrease cardiovascular events. Annals of medicine 2026. link 47 Suutari-Jääskö A, Parkkila K, Vähänikkilä H, Tulppo M, Perkiömäki J, Huikuri H et al.. Changes in leisure time physical activity, obesity-related morbidities, fatal and non-fatal CVD events and total mortality: Over 20-year follow-up in the opera study. PloS one 2026. link 48 Xie B, Fang Y, Lin F, Yang M, Liang Y, Liu B. Association of loneliness with incident cardiovascular diseases in middle-aged and older Chinese adults. PloS one 2026. link 49 Chaquila JA, Hernández-Vásquez A, Guerra Valencia J, Miranda-Torvisco F, Ramirez-Jeri G. Relative fat mass and cardiovascular risk in Peruvian adults: Findings from a national survey. PloS one 2026. link 50 Guimarães RM, Zajdhaft IT, Dos Santos LPR, Graever L, Araujo AV, da Silva DBC et al.. Comparison of Cardiovascular Disease Burden between Brazil and Denmark (1990-2021) Based on Global Burden of Disease: Availability of Universal Health System Is Not Enough. Global heart 2026. link 51 Hope E, Gonzalez AL, Norman LS, Smith HC, Wassenaar JW, Vickers KC et al.. Trained immunity: new paradigm in the immunological memory of cardiovascular disease. ImmunoHorizons 2026. link 52 Yang Q, Lu Y, Jiang X, Hu H, Lu X, Guo C. Enhanced cardiovascular disease risk prediction using integrated machine learning models: a study from the UK Biobank cohort. Open heart 2026. link 53 Abdollahi A, Ostovaneh A, Chehab O, Hoballah M, Matuck BRS, Wu CO et al.. Association Between Lipoprotein(a) and Cardiac Remodeling Across Race and Ethnicity in the Multi-Ethnic Study of Atherosclerosis. Circulation. Population health and outcomes 2026. link 54 Sinha A, Arrington J, Bashi A, Greene SJ, Jelovsek JE, Amundsen CL. The Association of Nocturia and Major Cardiovascular Events: A Bayesian Analysis. Urogynecology (Philadelphia, Pa.) 2026. link 55 Nagao H, Kondo Y, Kawada K, Fujishima Y, Shiode S, Uehara Y et al.. T-cadherin, a major adiponectin binding partner, suppresses ERK signaling in metabolic tissues. Proceedings of the National Academy of Sciences of the United States of America 2026. link 56 Bacmeister L, Glintborg D, Kjer-Møller JJ, Al-Jorani H, Christesen HT, Jensen TK et al.. Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease. JAMA cardiology 2026. link 57 Umphres SS, Alarabi AB, Ali HEA, Qadri S, Khasawneh FT, Alshbool FZ. The Prothrombotic Phenotype of Thirdhand Electronic Cigarette Exposure is Sex Independent and Involves Systemic Mediated Effects on Platelet Function: Evidence from a Mouse Model. Cardiovascular toxicology 2026. link 58 Hernandez AV, Diaz-Arocutipa C, Valenzuela G, Feigin V, Banda S, Barboza JJ et al.. Risk scoring for the primary prevention of cardiovascular disease. The Cochrane database of systematic reviews 2026. link 59 van Egeraat JWA, van Geloven N, Hageman SHJ, Bonten TN, Cahn W, Vos RC et al.. External validation of the SMART2 model for recurrent cardiovascular risk: performance in socioeconomic, ethnic and psychiatric subgroups. Open heart 2026. link 60 Boyer TM, Barrett RB, Xiong C, Bu F, Bhansali RA, Wallace AS et al.. Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women. Circulation 2026. link 61 Kahles F, Birkenfeld AL, Marx N. GLP-1 and the cardiovascular system. The Journal of clinical investigation 2026. link 62 Hornikel B, Dooley EE, Bowling CB, Chen B, Martinez-Amezcua P, Jacobs DR et al.. Development and validation of cardiorespiratory fitness prediction equations from 6-minute walk test: the Coronary Artery Risk Development in Adults (CARDIA) study. The journals of gerontology. Series A, Biological sciences and medical sciences 2026. link 63 Caramaschi S, Maus B, Olsson CM, Smedberg D, Kristen H, Whitehead M et al.. Linking everyday physical activity and capacity tests using wearable and mobile technologies in older adults and cardiac cohorts: protocol for a pilot observational study. BMJ open 2026. link 64 Shawer H, Cheng CW, Hemmings KE, Aldawsari AM, Revilla-González G, Stocco F et al.. A rare ORAI1 missense variant associates with risk of vascular diseases in White British adults. PloS one 2026. link 65 Obrycka P, Soczyńska J, Butyńska K, Frątczak A, Hałaburdo J, Gawełczyk W et al.. Impact of Early-Life Environmental Exposures and Potential Transgenerational Influence on the Risk of Coronary Artery Disease and Heart Failure. Cells 2026. link 66 Dardari ZA, Yao Z, Zhang J, Bakoyannis G, Nan H, Staten LK et al.. Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration. Circulation 2026. link 67 Hu J, Yang Y, Jiang Y, Wang Y, Zhu R, Zhang Z et al.. Erxian Decoction Ameliorates Myocardial Damage in Ovariectomized Rats by Regulating the Gut Microbiota and TMAO-Mediated NLRP3 Inflammatory Pathway. Journal of microbiology and biotechnology 2026. link 68 Inglis JM, Caughey GE, Liew D, Shakib S. Prevalence of multimorbidity and uptake of guideline-directed medicines for cardiovascular conditions in Australian hospitalised adults: a cross-sectional study. BMJ open 2026. link 69 Mena-Yi D, Ruiz-Díaz MS, Pérez-Castilla E, Mestra-Meriño S, Jiménez-Rodríguez L, Puerto-Lopez A et al.. Prevalence of Subclinical Carotid Atherosclerosis in Adults from the Colombian Caribbean Coast: Results from the Cartagena Cohort Study. The American journal of tropical medicine and hygiene 2026. link 70 Jin X, Cheng Z, Ding X, Liu Z. Research status and molecular mechanisms of disulfidptosis in cardiovascular diseases (Review). Molecular medicine reports 2026. link 71 Hennessy S, Penko J, Bellows BK, Coxson PG, Boylan R, Sims KD et al.. Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults. JAMA cardiology 2026. link 72 Bahit MC, Agudo-Quilez P, Zamorano J, Gibson CM. Cardiovascular adverse effects of common non-oncologic medications: from mechanisms to clinical management. European heart journal. Cardiovascular pharmacotherapy 2026. link 73 de Vautibault A, Mujanovic A, Amar V, Roten L, Fischer U, Zedde M et al.. Cardiovascular risk factor control in patients with covert brain infarcts in the prospective SILENT cohort study. European stroke journal 2026. link 74 Huynh S, Murphy F, Sabatier B, Pineau J, Extramiana F, Gandjbakhch E et al.. Reprocessing of single-use medical devices in cardiology: a systematic literature review of safety and performance characteristics applied to cardiac electrophysiology. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2026. link 75 Chevalley T, Bertholet F, Dübi M, Merli MS, Charmoy M, Bron S et al.. Preserved Function of Endothelial Colony-Forming Cells in Female Rats with Intrauterine Growth Restriction: Protection Against Arterial Hypertension and Arterial Stiffness?. Cells 2026. link 76 Vasilakopoulos V, Kanonidis I, Papadopoulou CI, Fragulis G, Ganatsios S. Impact of Lignite Combustion Air Pollution on Acute Coronary Syndrome and Atrial Fibrillation Incidence in Western Macedonia, Greece. International journal of environmental research and public health 2026. link 77 Münzel T, Lüscher T, Kramer CM, Churchwell K, Mbakwem A, Rajagopalan S. Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, the World Heart Federation. Global heart 2026. link 78 Beydoun HA, Beydoun MA, Tsai J, Tinker LF, Franceschini N, Nudy M et al.. Triglyceride-glucose index and cardiovascular disease by cardiovascular-kidney-metabolic syndrome and socioeconomic status among postmenopausal women. Atherosclerosis 2026. link 79 da Cruz MMA, de Roide LT, Manzatto ABO, Vanderlei LCM, Boro JVB, Franco MR et al.. Understanding Barriers and Facilitators to Cardiovascular Rehabilitation Participation Among Rural Residents With Cardiovascular Disease in Brazil. Public health nursing (Boston, Mass.) 2026. link 80 Song G. The C-reactive protein-triglyceride glucose index (CTI) predicts mortality in cardiovascular-kidney-metabolic syndrome: a dual-cohort study with machine learning validation. International journal of surgery (London, England) 2026. link 81 Ueda K, Nakamura SI, Kutara K, Ueda A, Ozaki K. Autopsy cases of aortic dissection, myxomatous valve degeneration, and ventricular septal defect in pet minipigs. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 2026. link 82 Münzel T, Lüscher T, Kramer CM, Churchwell K, Mbakwem A, Rajagopalan S. Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A Statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation. Circulation 2026. link 83 Bøg M, Bojesen AB, Emerson S, Ivkovic M, Jenkins NC, Lübker C et al.. Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial. PharmacoEconomics 2026. link 84 Aihaiti A, Saidaming A, Tuerxun H, Li N, Nijiati M. Prediction of cardiovascular mortality based on iron metabolism in patients with cardiovascular-kidney-metabolic syndrome: development and validation of clinical predictive model. European journal of medical research 2026. link 85 Ordunez P, Rosende A, Brettler J, Londono E, Van der Stuyft P, Martinez-Piedra R et al.. Readiness to deliver integrated cardiovascular, kidney and metabolic care in primary healthcare: phase II of HEARTS 2.0 in 26 countries in the Americas. BMJ global health 2026. link 86 Takahashi L, Tomiyama H, Kobori H, Hidaka Y, Orihara S, Uchida K et al.. The coiled-coil domain of myosin-11 as a potential biomarker to detect patients with atherosclerotic cardiovascular disease risk. The journal of physiological sciences : JPS 2026. link 87 Baugh CW, Gibson CM, Giannitsis E, Morrow DA, Januzzi JL, Papendick C et al.. Considerations for the Adoption of Digital Algorithms and Cardiovascular Decision-Support Tools in Clinical Practice. Critical pathways in cardiology 2026. link 88 Darvish S, Murray KO, Mahoney SA, VanDongen NS, Zigler MC, Ambrose C et al.. Late-Onset Menopause Attenuates Aortic Stiffness in the Postmenopausal Period. Hypertension (Dallas, Tex. : 1979) 2026. link 89 Tang TWH, Ullah K, Lee JJ, Chen HC, Hsieh PCH. Comparative insights into the gut-heart axis: cross-species and cross-population perspectives. Gut microbes 2026. link 90 Kishimoto S, Higashi Y. Recent advances and emerging perspectives in vascular and cardiovascular research: A 2025 update. Hypertension research : official journal of the Japanese Society of Hypertension 2026. link 91 Sarani Rad F, Bitaraf E, Jafarpour M, Li J. Technologies, Clinical Applications, and Implementation Barriers of Digital Twins in Precision Cardiology: Systematic Review. JMIR cardio 2026. link 92 Cheng YB, An DW, Zhang DY, Yu YL, Melgarejo JD, Boggia J et al.. End Point-Based Threshold for the Ambulatory Arterial Stiffness Index. Hypertension (Dallas, Tex. : 1979) 2026. link 93 Shea SA, Scheer FAJL, Gumz ML, Eikenberry SA, Qian J, Thosar SS et al.. Unlocking the potential of circadian biology for cardiovascular health. Physiological reviews 2026. link 94 Knobel P, Singhvi A, Krasnov H, Colicino E, Kloog I, Litke R et al.. Beyond greenness: multidimensional urban nature profiles and arteriosclerotic cardiovascular risk. Environment international 2026. link 95 Wilson L, Zhao Z, Divino V, Bassan M, Hartaigh BÓ, Stensen S et al.. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER). Diabetes, obesity & metabolism 2026. link 96 Baker CA, Johnson JJ, Hinds MT, Anderson DEJ. Thrombogenic characterization of alloyed and surface-modified magnesium bioresorbable metals for cardiovascular device applications. Biomaterials 2026. link 97 Marić I. Donor health beyond donation: cardiovascular risk factors in blood donor populations. A cross-sectional study. Blood transfusion = Trasfusione del sangue 2026. link 98 Yang Y, Lewey J, Arany Z. Cardiovascular complications of pregnancy. The Journal of clinical investigation 2026. link 99 Han J, Tang J, Zhao Y, Xiong J, Zhao S, Yue W et al.. Subendocardial Viability Ratio Is Associated With Target Organ Damage and Hints at a Potential Independent Predictor of Cardiovascular Mortality in Older Adults: A Prospective Cohort Study. Journal of the American Heart Association 2026. link 100 Rjoob K, McGurk KA, Zheng SL, Curran L, Ibrahim M, Zeng L et al.. A multimodal vision knowledge graph of cardiovascular disease. Nature cardiovascular research 2026. link

    Original source

    1. [1]
      Cost-Effectiveness of the Support and Services at Home (SASH) Program for Cardiovascular Risk Factors: A Community-Based Approach to Healthy Aging in Place. — Atherly A, Doerner C, Yan R, Schollmeyer J, Genge L, van den Broek-Altenburg E Health services research (2026)
    2. [2]
      Association Between Type D Personality and Cardiovascular Disease History: Cross-Sectional Study. — Grinberg K, Sela Y JMIR cardio (2026)
    3. [3]
      Early Identification of Cardiovascular Adverse Events Associated With Rofecoxib Using Real-World Data From the UK: A Nested Case-Control and Case-Crossover Study. — Moslemzadeh D, Souverein PC, Belitser SV, Heerdink ER, Klungel OH, Abtahi S Pharmacoepidemiology and drug safety (2026)
    4. [4]
      Impact of E-Cigarette Use on Circadian Proteins and Cardiovascular Risk Markers. — Alzu'bi A, Abu-El-Rub E, Khaswaneh RR, Al-Zubaidi M, Almomani W, Alenaizat A et al. Journal of cardiovascular translational research (2026)
    5. [5]
      Finding Significant Hits in Networks: a network-based tool for analyzing gene-level P-values to identify significant genes missed by standard methods. — Acharya S, Moghaddam VA, Jung WJ, Kang YS, Liao S, Province MA et al. Briefings in bioinformatics (2026)
    6. [6]
      Ferroptosis in cardiovascular diseases: molecular mechanisms and a novel therapeutic target. — Yu S, Pang Z, Fang H, Liu C Molecular biomedicine (2026)
    7. [7]
      Cardiovascular autonomic dysfunction is linked with arterial stiffness across glucose metabolism: the Maastricht study. — Schaarup JR, Bjerg L, Hansen CS, Andersen ST, van Greevenbroek MM, Schram MT et al. BMJ open diabetes research & care (2026)
    8. [8]
      Cardiometabolic index and cardiovascular disease incidence in middle-aged and older Chinese: A nationwide prospective cohort study. — Wu Y, Liu C, Wang T, Lin H, Su F Medicine (2026)
    9. [9]
      Hemoglobin A1c-systolic blood pressure index as a novel predictor of cardiovascular disease: evidence from three prospective cohorts. — Zhang R, Chen X, Zhou B, Xiang B, Zhu S Frontiers in endocrinology (2026)
    10. [10]
      Do adults with cardiovascular disease risk show meaningful reactivity to physical activity measurement? Coordinated analysis across six studies. — Arigo D, Baga K, Folk AL, Salvatore GM, Bercovitz I, Singh R et al. British journal of health psychology (2026)
    11. [11]
      Association between long-term exposure to artificial light at night and air pollution, and cardiovascular diseases in middle-aged and older adults. — Liu Z, Zang X, Li H, Fan Y, Sun Y, Yan C et al. PloS one (2026)
    12. [12]
      Revisiting the associations between cooking oils and survival among older people in China: A nationwide, community-based, prospective cohort study. — Wang K, Ban C, Zhao L, Ruan H, Wang Z, Zheng Y et al. PloS one (2026)
    13. [13]
      Nanozyme-Based Anti-Inflammatory Strategies in Cardiovascular Disease Management: Clinical Prospects and Challenges. — Zhou L, Song H, Xu T, Li G, Yuan Y, Liu C et al. International journal of nanomedicine (2026)
    14. [14]
      Is black carbon associated with cardiovascular and cancer mortality? Evidence from the Malmö Diet and Cancer Cohort. — Lawlor C, Malmqvist E, Oudin Åström D, Andersson Nystedt T, Bamberger J, Pira K et al. Global health action (2026)
    15. [15]
      American Heart Association's Life's Simple 7 for cardiovascular health assessment among Iranian adults: a national cross-sectional study from STEPwise approach to non-communicable diseases risk factor surveillance (STEPS) survey 2021. — Azadnajafabad S, Rezaei S, Almasi G, Ahmadi N, Golestani A, Rashidi MM et al. BMJ open (2026)
    16. [16]
      Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. — Lassen MCH, Ostrominski JW, Claggett BL, Wijkman MO, Lee J, Van't Hof JR et al. JAMA cardiology (2026)
    17. [17]
      The distribution of incidence rates of cardiovascular diseases in the elderly and the relationship between dietary patterns and cardiovascular risk. — Yang Q, Liu J PeerJ (2026)
    18. [18]
      Physician Disagreement With Guidelines as a Critical Barrier to Achieving LDL-C Targets in Very High-Risk Patients: An Implementation Science Study. — Cho KH, Cho YR, Lee SR, Bae JW, Nam CW, Park Y et al. Journal of Korean medical science (2026)
    19. [19]
      Macrophage efferocytosis in cardiovascular disease: mechanisms and therapeutic implications. — Gupta N, Liu Y, Cai B ImmunoHorizons (2026)
    20. [20]
      Role of Cardiopulmonary Exercise Testing in the Monitoring of Cardiovascular Risk Factors in Athletes - State-of-the-Art Review. — Kasiak P Vascular health and risk management (2026)
    21. [21]
      Multilayer Timing of Cardiac Circadian Regulation Informs Prevention and Treatment of Cardiovascular Disease. — Zhu L, Qian B, Zhang X, Hu LL Vascular health and risk management (2026)
    22. [22]
      Depression may not be an independent risk factor for mortality in patients with cardiovascular disease: data from NHANES 2011-2018. — Nguyen BT, Li YC, Dang HN, Nguyen HT, Thai NTH, Nguyen DT et al. Open heart (2026)
    23. [23]
      Consumption of Terminalia catappa powder: modulation of lipid metabolism, reduction of cardiovascular risk, and hepatic protection in aged Wistar rats. — Dantas BS, Pereira DE, Oliveira ND, Oliveira ACS, Dutra LMG, Silva JDL et al. Biogerontology (2026)
    24. [24]
      Long-term exposure to particulate matter from road traffic and residential heating and mortality: a multi-cohort study in Sweden. — Stockfelt L, Forsberg B, Andersson EM, Andersson N, Sallsten G, Segersson D et al. Scientific reports (2026)
    25. [25]
      Association of novel lipid markers with cardiovascular and cerebrovascular disease risk: A cross-sectional NHANES 1999 to 2018 study. — Guan L, Su T, Xin S, Zhang Y, Wang B, Wang X et al. Medicine (2026)
    26. [26]
      High mobility group box 1: DAMPening the danger molecule in cardiovascular disease with exercise. — Liao YC, Goh J Cell stress & chaperones (2026)
    27. [27]
      Association Between NHHR and Future Cardiovascular Disease Among Patients With CKM Stages 0-3: A Nationwide Prospective Cohort Study. — Huang Y, Gao Y, Shao J, Wang K, Ma Y, Ai L et al. Journal of clinical hypertension (Greenwich, Conn.) (2026)
    28. [28]
      Prototype Learning to Create Refined Interpretable Digital Phenotypes from ECGs. — Sethi S, Chen D, Burkhart MC, Bhandari N, Ramadan B, Beaulieu-Jones B Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing (2026)
    29. [29]
      Cardiovascular mortality associated with testosterone therapy in cisgender women and transgender men: a systematic review. — Viana DPDC, Câmara LC, Alto LSM Frontiers in endocrinology (2026)
    30. [30]
      (no title) — Novillo A, Ysbert M, Brea R, Hidalgo-Estévez AM, El Abdellaoui-Soussi F, Gómez-Del Arco P Human mutation (2026)
    31. [31]
      Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors. — Tomaru JM, Nunes IR, Santiago CFS, Otoboni AMMB, Mendes CG, Fiorini AMR et al. Nutrients (2026)
    32. [32]
      Erectile and Clitoral Dysfunction as Harbingers of Cardiovascular Disease: A Perspective. — Priviero F, Hollis F, Wood SK, Uline M, Andersson KE, Webb RC Medicina (Kaunas, Lithuania) (2026)
    33. [33]
      Mental Health, Trauma, and Cardiovascular Risk Within South Asian Diaspora. — Sinha J International journal of environmental research and public health (2026)
    34. [34]
      Diversity and Representation in Cardiovascular Research: Evidence Gaps, Emerging Models, and Policy Implications. — Grewal S, Wildish J, Chalmers C, Dedding C, Suurmond J, Agyemang C et al. International journal of environmental research and public health (2026)
    35. [35]
      Special Issue "Cellular and Molecular Progression of Cardiovascular Diseases". — Borghini A, Rizza A, Tonacci A International journal of molecular sciences (2026)
    36. [36]
      STAT-Mediated Mitochondrial Regulation in Cardiovascular Diseases: Mechanistic Insights and STAT3-Focused Therapeutic Strategies. — Guo B, Fu Y, Wang M, Zhu L, He X Biomolecules (2026)
    37. [37]
      Relationship between the urinary albumin-to-creatinine ratio and cardiovascular adverse outcomes in the Beijing community population: a prospective cohort study. — Liu S, Jia J, Huo Y, Fan F, Zhang Y BMJ open (2026)
    38. [38]
      Associations of oxidative balance score with mortality and cardiovascular events: cohort study from NHANES and UK Biobank. — Zhang H, Chen S, Bai X, Zhou X, Zhang F, Wang X et al. BMJ open (2026)
    39. [39]
      Adenosine-to-Inosine (A-to-I) RNA Editing by ADAR1 to Control RNA Sensing in Cardiovascular Disease. — Weldy CS, Li JB, Quertermous T Arteriosclerosis, thrombosis, and vascular biology (2026)
    40. [40]
      Considerations in the Use of Mouse Models of Vascular and Valvular Calcification. — Hsu JJ, Li Q, Tintut Y, Demer LL Arteriosclerosis, thrombosis, and vascular biology (2026)
    41. [41]
      The prevalence of obesity and hypertension in paediatric cardiology patients before and after COVID-19 lockdown measures. — Ball J, Kenny JH, Kotidis C European journal of pediatrics (2026)
    42. [42]
      Advancing cardiovascular imaging in Iraq: infrastructure, gender diversity, and future perspectives. — Farhan HA, Al-Jorani MS Therapeutic advances in cardiovascular disease (2026)
    43. [43]
      Photon-Counting CT in Cardiovascular Imaging: Clinical Applications. — Rajiah PS, Williams JM, LaVere M, Leng S, Young PM Korean journal of radiology (2026)
    44. [44]
      Comparison of different glycemic control indicators on incidence of acute kidney injury and long-term mortality in critically ill patients with atherosclerotic cardiovascular disease: A retrospective cohort study. — Zhang D, Shi L, Wang J PloS one (2026)
    45. [45]
      Association between Dysgeusia and Atherosclerotic Cardiovascular Disease: A Cross-Sectional Study With Propensity Score-Matched Analyses. — Zhou P, Zhou X, Tang S, Liang D, Wu D Oral health & preventive dentistry (2026)
    46. [46]
      Ezetimibe alone for over 75 years old as a primary prevention to decrease cardiovascular events. — Vuorio A, Kovanen PT, Strandberg T Annals of medicine (2026)
    47. [47]
      Changes in leisure time physical activity, obesity-related morbidities, fatal and non-fatal CVD events and total mortality: Over 20-year follow-up in the opera study. — Suutari-Jääskö A, Parkkila K, Vähänikkilä H, Tulppo M, Perkiömäki J, Huikuri H et al. PloS one (2026)
    48. [48]
      Association of loneliness with incident cardiovascular diseases in middle-aged and older Chinese adults. — Xie B, Fang Y, Lin F, Yang M, Liang Y, Liu B PloS one (2026)
    49. [49]
      Relative fat mass and cardiovascular risk in Peruvian adults: Findings from a national survey. — Chaquila JA, Hernández-Vásquez A, Guerra Valencia J, Miranda-Torvisco F, Ramirez-Jeri G PloS one (2026)
    50. [50]
      Comparison of Cardiovascular Disease Burden between Brazil and Denmark (1990-2021) Based on Global Burden of Disease: Availability of Universal Health System Is Not Enough. — Guimarães RM, Zajdhaft IT, Dos Santos LPR, Graever L, Araujo AV, da Silva DBC et al. Global heart (2026)
    51. [51]
      Trained immunity: new paradigm in the immunological memory of cardiovascular disease. — Hope E, Gonzalez AL, Norman LS, Smith HC, Wassenaar JW, Vickers KC et al. ImmunoHorizons (2026)
    52. [52]
      Enhanced cardiovascular disease risk prediction using integrated machine learning models: a study from the UK Biobank cohort. — Yang Q, Lu Y, Jiang X, Hu H, Lu X, Guo C Open heart (2026)
    53. [53]
      Association Between Lipoprotein(a) and Cardiac Remodeling Across Race and Ethnicity in the Multi-Ethnic Study of Atherosclerosis. — Abdollahi A, Ostovaneh A, Chehab O, Hoballah M, Matuck BRS, Wu CO et al. Circulation. Population health and outcomes (2026)
    54. [54]
      The Association of Nocturia and Major Cardiovascular Events: A Bayesian Analysis. — Sinha A, Arrington J, Bashi A, Greene SJ, Jelovsek JE, Amundsen CL Urogynecology (Philadelphia, Pa.) (2026)
    55. [55]
      T-cadherin, a major adiponectin binding partner, suppresses ERK signaling in metabolic tissues. — Nagao H, Kondo Y, Kawada K, Fujishima Y, Shiode S, Uehara Y et al. Proceedings of the National Academy of Sciences of the United States of America (2026)
    56. [56]
      Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease. — Bacmeister L, Glintborg D, Kjer-Møller JJ, Al-Jorani H, Christesen HT, Jensen TK et al. JAMA cardiology (2026)
    57. [57]
      The Prothrombotic Phenotype of Thirdhand Electronic Cigarette Exposure is Sex Independent and Involves Systemic Mediated Effects on Platelet Function: Evidence from a Mouse Model. — Umphres SS, Alarabi AB, Ali HEA, Qadri S, Khasawneh FT, Alshbool FZ Cardiovascular toxicology (2026)
    58. [58]
      Risk scoring for the primary prevention of cardiovascular disease. — Hernandez AV, Diaz-Arocutipa C, Valenzuela G, Feigin V, Banda S, Barboza JJ et al. The Cochrane database of systematic reviews (2026)
    59. [59]
      External validation of the SMART2 model for recurrent cardiovascular risk: performance in socioeconomic, ethnic and psychiatric subgroups. — van Egeraat JWA, van Geloven N, Hageman SHJ, Bonten TN, Cahn W, Vos RC et al. Open heart (2026)
    60. [60]
      Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women. — Boyer TM, Barrett RB, Xiong C, Bu F, Bhansali RA, Wallace AS et al. Circulation (2026)
    61. [61]
      GLP-1 and the cardiovascular system. — Kahles F, Birkenfeld AL, Marx N The Journal of clinical investigation (2026)
    62. [62]
      Development and validation of cardiorespiratory fitness prediction equations from 6-minute walk test: the Coronary Artery Risk Development in Adults (CARDIA) study. — Hornikel B, Dooley EE, Bowling CB, Chen B, Martinez-Amezcua P, Jacobs DR et al. The journals of gerontology. Series A, Biological sciences and medical sciences (2026)
    63. [63]
      Linking everyday physical activity and capacity tests using wearable and mobile technologies in older adults and cardiac cohorts: protocol for a pilot observational study. — Caramaschi S, Maus B, Olsson CM, Smedberg D, Kristen H, Whitehead M et al. BMJ open (2026)
    64. [64]
      A rare ORAI1 missense variant associates with risk of vascular diseases in White British adults. — Shawer H, Cheng CW, Hemmings KE, Aldawsari AM, Revilla-González G, Stocco F et al. PloS one (2026)
    65. [65]
      Impact of Early-Life Environmental Exposures and Potential Transgenerational Influence on the Risk of Coronary Artery Disease and Heart Failure. — Obrycka P, Soczyńska J, Butyńska K, Frątczak A, Hałaburdo J, Gawełczyk W et al. Cells (2026)
    66. [66]
      Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration. — Dardari ZA, Yao Z, Zhang J, Bakoyannis G, Nan H, Staten LK et al. Circulation (2026)
    67. [67]
      Erxian Decoction Ameliorates Myocardial Damage in Ovariectomized Rats by Regulating the Gut Microbiota and TMAO-Mediated NLRP3 Inflammatory Pathway. — Hu J, Yang Y, Jiang Y, Wang Y, Zhu R, Zhang Z et al. Journal of microbiology and biotechnology (2026)
    68. [68]
      Prevalence of multimorbidity and uptake of guideline-directed medicines for cardiovascular conditions in Australian hospitalised adults: a cross-sectional study. — Inglis JM, Caughey GE, Liew D, Shakib S BMJ open (2026)
    69. [69]
      Prevalence of Subclinical Carotid Atherosclerosis in Adults from the Colombian Caribbean Coast: Results from the Cartagena Cohort Study. — Mena-Yi D, Ruiz-Díaz MS, Pérez-Castilla E, Mestra-Meriño S, Jiménez-Rodríguez L, Puerto-Lopez A et al. The American journal of tropical medicine and hygiene (2026)
    70. [70]
      Research status and molecular mechanisms of disulfidptosis in cardiovascular diseases (Review). — Jin X, Cheng Z, Ding X, Liu Z Molecular medicine reports (2026)
    71. [71]
      Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults. — Hennessy S, Penko J, Bellows BK, Coxson PG, Boylan R, Sims KD et al. JAMA cardiology (2026)
    72. [72]
      Cardiovascular adverse effects of common non-oncologic medications: from mechanisms to clinical management. — Bahit MC, Agudo-Quilez P, Zamorano J, Gibson CM European heart journal. Cardiovascular pharmacotherapy (2026)
    73. [73]
      Cardiovascular risk factor control in patients with covert brain infarcts in the prospective SILENT cohort study. — de Vautibault A, Mujanovic A, Amar V, Roten L, Fischer U, Zedde M et al. European stroke journal (2026)
    74. [74]
      Reprocessing of single-use medical devices in cardiology: a systematic literature review of safety and performance characteristics applied to cardiac electrophysiology. — Huynh S, Murphy F, Sabatier B, Pineau J, Extramiana F, Gandjbakhch E et al. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026)
    75. [75]
      Preserved Function of Endothelial Colony-Forming Cells in Female Rats with Intrauterine Growth Restriction: Protection Against Arterial Hypertension and Arterial Stiffness? — Chevalley T, Bertholet F, Dübi M, Merli MS, Charmoy M, Bron S et al. Cells (2026)
    76. [76]
      Impact of Lignite Combustion Air Pollution on Acute Coronary Syndrome and Atrial Fibrillation Incidence in Western Macedonia, Greece. — Vasilakopoulos V, Kanonidis I, Papadopoulou CI, Fragulis G, Ganatsios S International journal of environmental research and public health (2026)
    77. [77]
      Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, the World Heart Federation. — Münzel T, Lüscher T, Kramer CM, Churchwell K, Mbakwem A, Rajagopalan S Global heart (2026)
    78. [78]
      Triglyceride-glucose index and cardiovascular disease by cardiovascular-kidney-metabolic syndrome and socioeconomic status among postmenopausal women. — Beydoun HA, Beydoun MA, Tsai J, Tinker LF, Franceschini N, Nudy M et al. Atherosclerosis (2026)
    79. [79]
      Understanding Barriers and Facilitators to Cardiovascular Rehabilitation Participation Among Rural Residents With Cardiovascular Disease in Brazil. — da Cruz MMA, de Roide LT, Manzatto ABO, Vanderlei LCM, Boro JVB, Franco MR et al. Public health nursing (Boston, Mass.) (2026)
    80. [80]
      The C-reactive protein-triglyceride glucose index (CTI) predicts mortality in cardiovascular-kidney-metabolic syndrome: a dual-cohort study with machine learning validation. — Song G International journal of surgery (London, England) (2026)
    81. [81]
      Autopsy cases of aortic dissection, myxomatous valve degeneration, and ventricular septal defect in pet minipigs. — Ueda K, Nakamura SI, Kutara K, Ueda A, Ozaki K Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc (2026)
    82. [82]
      Environmental Stressors and Cardiovascular Health: Acting Locally for Global Impact in a Changing World: A Statement of the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation. — Münzel T, Lüscher T, Kramer CM, Churchwell K, Mbakwem A, Rajagopalan S Circulation (2026)
    83. [83]
      Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial. — Bøg M, Bojesen AB, Emerson S, Ivkovic M, Jenkins NC, Lübker C et al. PharmacoEconomics (2026)
    84. [84]
      Prediction of cardiovascular mortality based on iron metabolism in patients with cardiovascular-kidney-metabolic syndrome: development and validation of clinical predictive model. — Aihaiti A, Saidaming A, Tuerxun H, Li N, Nijiati M European journal of medical research (2026)
    85. [85]
      Readiness to deliver integrated cardiovascular, kidney and metabolic care in primary healthcare: phase II of HEARTS 2.0 in 26 countries in the Americas. — Ordunez P, Rosende A, Brettler J, Londono E, Van der Stuyft P, Martinez-Piedra R et al. BMJ global health (2026)
    86. [86]
      The coiled-coil domain of myosin-11 as a potential biomarker to detect patients with atherosclerotic cardiovascular disease risk. — Takahashi L, Tomiyama H, Kobori H, Hidaka Y, Orihara S, Uchida K et al. The journal of physiological sciences : JPS (2026)
    87. [87]
      Considerations for the Adoption of Digital Algorithms and Cardiovascular Decision-Support Tools in Clinical Practice. — Baugh CW, Gibson CM, Giannitsis E, Morrow DA, Januzzi JL, Papendick C et al. Critical pathways in cardiology (2026)
    88. [88]
      Late-Onset Menopause Attenuates Aortic Stiffness in the Postmenopausal Period. — Darvish S, Murray KO, Mahoney SA, VanDongen NS, Zigler MC, Ambrose C et al. Hypertension (Dallas, Tex. : 1979) (2026)
    89. [89]
      Comparative insights into the gut-heart axis: cross-species and cross-population perspectives. — Tang TWH, Ullah K, Lee JJ, Chen HC, Hsieh PCH Gut microbes (2026)
    90. [90]
      Recent advances and emerging perspectives in vascular and cardiovascular research: A 2025 update. — Kishimoto S, Higashi Y Hypertension research : official journal of the Japanese Society of Hypertension (2026)
    91. [91]
      Technologies, Clinical Applications, and Implementation Barriers of Digital Twins in Precision Cardiology: Systematic Review. — Sarani Rad F, Bitaraf E, Jafarpour M, Li J JMIR cardio (2026)
    92. [92]
      End Point-Based Threshold for the Ambulatory Arterial Stiffness Index. — Cheng YB, An DW, Zhang DY, Yu YL, Melgarejo JD, Boggia J et al. Hypertension (Dallas, Tex. : 1979) (2026)
    93. [93]
      Unlocking the potential of circadian biology for cardiovascular health. — Shea SA, Scheer FAJL, Gumz ML, Eikenberry SA, Qian J, Thosar SS et al. Physiological reviews (2026)
    94. [94]
      Beyond greenness: multidimensional urban nature profiles and arteriosclerotic cardiovascular risk. — Knobel P, Singhvi A, Krasnov H, Colicino E, Kloog I, Litke R et al. Environment international (2026)
    95. [95]
      Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER). — Wilson L, Zhao Z, Divino V, Bassan M, Hartaigh BÓ, Stensen S et al. Diabetes, obesity & metabolism (2026)
    96. [96]
      Thrombogenic characterization of alloyed and surface-modified magnesium bioresorbable metals for cardiovascular device applications. — Baker CA, Johnson JJ, Hinds MT, Anderson DEJ Biomaterials (2026)
    97. [97]
      Donor health beyond donation: cardiovascular risk factors in blood donor populations. A cross-sectional study. — Marić I Blood transfusion = Trasfusione del sangue (2026)
    98. [98]
      Cardiovascular complications of pregnancy. — Yang Y, Lewey J, Arany Z The Journal of clinical investigation (2026)
    99. [99]
      Subendocardial Viability Ratio Is Associated With Target Organ Damage and Hints at a Potential Independent Predictor of Cardiovascular Mortality in Older Adults: A Prospective Cohort Study. — Han J, Tang J, Zhao Y, Xiong J, Zhao S, Yue W et al. Journal of the American Heart Association (2026)
    100. [100]
      A multimodal vision knowledge graph of cardiovascular disease. — Rjoob K, McGurk KA, Zheng SL, Curran L, Ibrahim M, Zeng L et al. Nature cardiovascular research (2026)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG